Mesoblast Limited
MESO · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $2 | $2 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $2 | $2 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 0% | 344.9% | 0% | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | -231.1% | -231.1% | -107.8% | -107.8% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -279.7% | -279.7% | -599.1% | -599.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -386% | -386% | -1,518.8% | -1,518.8% |
| EPS Diluted | -0.21 | -0.21 | -0.21 | -0.21 |
| % Growth | 0% | 0% | 0% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |